Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis

Stopped early · Phase 3

Conditions studied: Sepsis

In brief

The objective of this study is to demonstrate that rPAF-AH is safe and reduces 28 day all cause mortality in patients with severe sepsis.

Key facts

Study ID

NCT00037687

Run by

ICOS Corporation

People needed

2500

Starts

2001-04-01

Expected to finish

2004-12-01

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of severe sepsis
• At least 18 years old
• Patient or legally authorized representative able to provide informed consent

You may not qualify if…

• Severe lung injury (acute respiratory distress syndrome)
• Immunocompromised
• Severe liver disease
• Inflammation of the pancreas, organ rejection, or burns to more than 30% of body
• Enrolled in another clinical trial
• Already participated in this or other rPAF-AH study
• There is not a commitment to aggressive treatment
• Has a disease with life expectancy less than 6 months

Where it is running

• Mary E. Lonien, M.S. — Bothell, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.